X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PHSU05 (ensereptide) is a synthetic peptide derived from human lactoferricin peptide, it inhibits the release of pro-inflammatory cytokines, such as IL-1β, IL-6 and Il-8 as well as TNF- alpha, to prevent post-surgical adhesions and scar formation.
Lead Product(s): Ensereptide
Therapeutic Area: Dermatology Product Name: PHSU05
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
PXL01 (ensereptide) is a synthetic peptide derived from human lactoferricin peptide, it inhibits the release of pro-inflammatory cytokines, such as IL-1β, IL-6 and Il-8 as well as TNF- alpha, to prevent post-surgical adhesions and scar formation.
Lead Product(s): Ensereptide
Therapeutic Area: Dermatology Product Name: PXL01
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
The company's ensereptide program is currently focused on the prevention of skin scarring associated with surgery or trauma. In the spring, a total of 24 subjects completed the clinical study protocol according to plan in the phase II study with ensereptide, PHSU05.
Lead Product(s): Ensereptide
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
The most important finding from that clinical trial was that ropocamptide (LL-37) shows a significant effect in the patient subgroup with large wounds (≥10 cm2).
Lead Product(s): Ropocamptide
Therapeutic Area: Podiatry Product Name: LL-37
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
The company's ensereptide program is focused on the prevention of skin scarring in conjunction with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of tissue adhesions after hand and spine surgery.
Lead Product(s): Ensereptide
Therapeutic Area: Dermatology Product Name: PXL01
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Pergamum AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
